4.8 Article

Passive Transfer of Vaccine-Elicited Antibodies Protects against SIV in Rhesus Macaques

Journal

CELL
Volume 183, Issue 1, Pages 185-+

Publisher

CELL PRESS
DOI: 10.1016/j.cell.2020.08.033

Keywords

-

Funding

  1. National Institutes of Health [AI060354, AI080289, AI102660, AI124377, AI126603, AI128751, AI129797, OD024917]
  2. Samana Cay MGH Scholar Program
  3. Ragon Institute of MGH, MIT and Harvard

Ask authors/readers for more resources

Several HIV-1 and SIV vaccine candidates have shown partial protection against viral challenges in rhesus macaques. However, the protective efficacy of vaccine-elicited polyclonal antibodies has not previously been demonstrated in adoptive transfer studies in nonhuman primates. In this study, we show that passive transfer of purified antibodies from vaccinated macaques can protect naive animals against SIVmac251 challenges. We vaccinated 30 rhesus macaques with Ad26-SIV Env/Gag/Pol and SIV Env gp140 protein vaccines and assessed the induction of antibody responses and a putative protective signature. This signature included multiple antibody functions and correlated with upregulation of interferon pathways in vaccinated animals. Adoptive transfer of purified immunoglobulin G (IgG) from the vaccinated animals with the most robust protective signatures provided partial protection against SIVmac251 challenges in naive recipient rhesus macaques. These data demonstrate the protective efficacy of purified vaccine-elicited antiviral antibodies in this model, even in the absence of virus neutralization.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available